In addition, single anti-PD-1, single anti-LAG-3, single anti-KLRG1 (killer cell lectin-like receptor subfamily G member 1 antibody), and double anti-PD-1/KLRG1 resulted in little or no improvements in CLL progression [68]. This evidence concerns the gene LAG3 and B-cell chronic lymphocytic leukemia.